Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OABI vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MXCT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 2–6 Matrix Metrics)

MXCT Overall Winner 6-Pillar Tally: OABI 2 – 3 MXCT (1 Tie) Matrix Metrics: OABI 6 – 2 MXCT

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over OmniAb, Inc. (OABI) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Composite vs. Pillar Nuance: While OABI currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -92.9% operating margin) and revenue trajectory (+48.7% vs. +78.3% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OABI vs MXCT
OABI NASDAQ
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$4.66
-7.36% 1D
Market Cap $733.7M
TTM Revenue $40M
Forward P/E N/M
Beta / 30D Vol 1.24β · 60% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.9 · SMA20: $5.03 · SMA50: $4.82
MXCT NASDAQ Head-to-Head Winner
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (OABI 2 – 3 MXCT)

Columns: Metric · OABI · MXCT
1. Valuation Multiples MXCT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.1x 3.9x
2. Growth & Scale OABI
Revenue Growth (YoY) +78.3% +48.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $40M $34M
Market Cap $733.7M $132.2M
3. Profitability & Quality MXCT
Gross Margin 97.7% 81.0%
Operating Margin -92.9% -85.5%
Net Profit Margin -108.1% -81.4%
Return on Equity (ROE) -16.5% -16.9%
4. Balance Sheet & Cash Flow OABI
Cash Generation (TTM) $2.4M -$24M
Cash Flow Margin 5.9% -69.2%
Net Cash / Leverage $4.7M Net Cash $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 101.7% (14th %ile) N/A (N/A)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OABI (6) vs MXCT (2)
Institutional Metric OABI MXCT Criterion Row Edge
Market Capitalization
Scale
$733.7M $132.2M Larger Scale OABI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+78.3% +48.7% Higher Growth OABI
Operating Margin (TTM)
Profitability
-92.9% -85.5% Higher Margin MXCT
Net Profit Margin
Profitability
-108.1% -81.4% Higher Margin MXCT
Return on Equity (ROE)
Capital Efficiency
-16.5% -16.9% Higher ROE OABI
52-Week Range Position
Momentum
81% ($1–$5) 63% ($1–$2) Stronger Trend OABI
Beta / 30D Volatility
Risk Regime
1.24β · 60% Vol 1.19β · 96% Vol Lower Realized Risk OABI
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite OABI
Trailing 12M Revenue (USD)
Operating Scale
$40M $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.7% 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.1x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.4M ($4.7M Net Cash) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OABI +1.69 pp
OABI: -2.51% · MXCT: -4.2%
3M Horizon OABI +0.38 pp
OABI: -1.06% · MXCT: -1.44%
6M Horizon OABI +44.12 pp
OABI: +75.85% · MXCT: +31.73%
1Y Horizon OABI +201.83 pp
OABI: +182.42% · MXCT: -19.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OABI Revenue MXCT Revenue OABI Op. Margin MXCT Op. Margin Margin Leader
FY2019 N/A $10M N/A -93.7% MXCT
FY2020 N/A $20M N/A -71.6% MXCT
FY2021 $30M $20M -102.5% -84.3% MXCT
FY2022 $60M $30M -45.1% -95.2% OABI
FY2023 $30M $20M -203.2% -247.7% OABI
FY2024 $30M $20M -282.3% -230.5% MXCT
FY2025 $20M $20M -369.5% -247.6% MXCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OABI CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 101.7%
IV Percentile 14th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OABI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $733.7M market capitalization and -92.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OABI vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over OmniAb, Inc. (OABI) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OABI carries a Unified Composite Score of 45.5/100 (HOLD) at $4.66 (N/M Forward P/E, -92.9% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Composite vs. Pillar Nuance: While OABI currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (2–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -92.9% operating margin) and revenue trajectory (+48.7% vs. +78.3% YoY).

OABI leads the Growth & Scale pillar: OABI posts +78.3% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (97.7% gross margin, -92.9% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), OABI cumulative revenue shifted -33.3% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, OABI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

MXCT screens cheaper on headline valuation multiples. OABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.1x EV/Revenue (5.9% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OABI (-16.5% ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, OABI carries 101.7% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.24β · 60% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.